Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-08-20

Clinical Trial Update: A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of Farletuzumab in adenocarcinoma of the lung has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Farletuzumab (farletuzumab)

Snippet

Sponsor: Morphotek | Conditions: Adenocarcinoma of the Lung | Phase 2 | Status: COMPLETED | Results posted: 2020-08-20